Adam P. Dicker on Muck Rack

Adam P. Dicker

Philadelphia
As seen in: JCO- Clinical Cancer Informatics, Wiley, JAMA: Journal of the American Medical Association, The Lancet, Journal of Clinical Oncology, ONCOLOGY journal, OncLive, UroToday, Oncology Nursing News, OnlineDomain.com
Physician-scientist leading an Oncology Dept and Center for AI & Digital Health | Computational Oncology: molecular diagnostics to health care delivery |
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Adam P.

Contact Adam P., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

For Sale - TransgenderPeople.com 3k, characterdefamation.com, 3k socialmediacover.com 3k - Dynadot

|
By Adam P. Dicker
| dnforum.com
Membership is FREE – with unlimited access to all features, tools, and discussions. Premium accounts get benefits like banner ads and newsletter exposure. ✅ Signature links are now free for all. 🚫 No AI-generated (LLM) posts allowed. Share your own thoughts and experience — accounts may be terminated for violations. You are using an out of date browser. It may not display this or other websites correctly. You should upgrade or use an alternative browser.
Open in Who Shared View Duplicates (18) Issue with article?

Multimodal Artificial Intelligence Concordance Between Whole-Mount Specimens and Tissue Microarrays in Prostate Cancer Analysis - Adam Dicker

|
By Adam P. Dicker
| UroToday Verified
Read the Full Video Transcript Alicia Morgans: Hi. I'm so excited to be here today, talking with Dr. Adam Dicker at GU ASCO 2025. He's joining me from Thomas Jefferson University. Thank you so much for being here. Adam P. Dicker: My pleasure. Alicia Morgans: Wonderful. So there's been a lot of excitement about MMAI, this artificial intelligence that helps us really understand pathology specimens on a deeper level, maybe being prognostic or predictive of certain outcomes for patients.
Open in Who Shared Issue with article?

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma | Journal of Clinical Oncology

|
By Christina Tsien, Stephanie Pugh, Adam P. Dicker, Jeffrey J. Raizer
| ascopubs.org
Article Tools ORIGINAL REPORTS Neurooncology Abstract Full Text PDF Figures and Tables Supplements Abstract To assess whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS), compared with BEV alone in recurrent glioblastoma (GBM). The primary objective was OS, and secondary objectives included PFS, response rate, and treatment adverse events (AEs) including delayed CNS toxicities.
Open in Who Shared Issue with article?
See all 19 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified